TAK in the 13F filings
Takeda Pharmaceutical Co Ltd · CUSIP 874060205
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 17
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 3 listed it in both
- Shares listed
- 37,529,269
- combined, among listed positions
- Reported value
- $695m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 13 buyers (opened or added shares) and 7 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +4,010,029.
Managers listing TAK in Q1 2026
17 of 17 holders
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsexisting position · 19,104,219 shares now+5,617,447
- Fidelity (FMR LLC)existing position · 7,117,486 shares now+3,060,618
- Renaissance Technologies LLCexisting position · 2,989,100 shares now+370,800
- Two Sigma Investments LPnew position · 311,700 shares now+311,700
- Citadel Advisors LLCexisting position · 624,160 shares now+234,426
Reductions
- Arrowstreet Capital LPexisting position · 3,116,311 shares now-2,566,536
- D. E. Shaw & Co.existing position · 2,602,543 shares now-1,691,207
- Acadian Asset Management LLCexisting position · 7,673 shares now-20,668
- Balyasny Asset Management LLCexisting position · 140,578 shares now-446
New positions and exits
New (5)
Exited (3)
- Voloridge Investment Management LLCwas $15m
- Millennium Management LLCwas $14m
- Schonfeld Strategic Advisors LLCwas $1.8m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2018 | 3 | $83m | n.a. | n.a. |
| Q1 2019 | 12 | $1.2bn | n.a. | n.a. |
| Q2 2019 | 6 | $721m | n.a. | n.a. |
| Q3 2019 | 9 | $718m | n.a. | n.a. |
| Q4 2019 | 6 | $645m | n.a. | n.a. |
| Q1 2020 | 4 | $362m | n.a. | n.a. |
| Q2 2020 | 4 | $395m | n.a. | n.a. |
| Q3 2020 | 4 | $423m | n.a. | n.a. |
| Q4 2020 | 5 | $549m | n.a. | n.a. |
| Q1 2021 | 4 | $699m | n.a. | n.a. |
| Q2 2021 | 4 | $476m | n.a. | n.a. |
| Q3 2021 | 4 | $410m | n.a. | n.a. |
| Q4 2021 | 2 | $111m | n.a. | n.a. |
| Q2 2022 | 3 | $69m | n.a. | n.a. |
| Q3 2022 | 3 | $68m | n.a. | n.a. |
| Q4 2022 | 5 | $208m | n.a. | n.a. |
| Q1 2023 | 5 | $349m | n.a. | n.a. |
| Q2 2023 | 5 | $353m | n.a. | n.a. |
| Q3 2023 | 4 | $311m | n.a. | n.a. |
| Q4 2023 | 5 | $374m | 4 | 1 |
| Q1 2024 | 3 | $228m | 0 | 2 |
| Q2 2024 | 4 | $243m | 3 | 1 |
| Q3 2024 | 3 | $236m | 2 | 1 |
| Q4 2024 | 3 | $271m | 1 | 2 |
| Q1 2025 | 3 | $256m | 3 | 0 |
| Q2 2025 | 2 | $257m | 2 | 0 |
| Q3 2025 | 2 | $253m | 2 | 0 |
| Q4 2025 | 4 | $355m | 11 | 8 |
| Q1 2026 | 3 | $467m | 13 | 7 |
| Q2 2026 | 3 | $410m | 13 | 10 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TAK and LLY →TAK and JNJ →TAK and VRTX →Choose a stock to compare with TAK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TAK, latest filings →Back to the 13F Explorer →